ROCK2-IN-13
ROCK2-IN-13 is a selective ROCK2 inhibitor. ROCK2-IN-13 reduces nuclear expression by disrupting the interaction of ROCK2 with transcriptional co activators p300> and PGC 1α, repressing oncogenic transcription. ROCK2-IN-13 activates FOXO1 driven PTEN expression, leading to suppression of the PI3K/Akt pathway, induction of G2/M cell cycle arrest, and promotion of apoptosis. ROCK2-IN-13 ablates the nuclear transcriptional function of ROCK2 that sustains oncogenic signaling and restores the tumor suppressive PTEN/FOXO1 axis. ROCK2-IN-13 can be used for prostate cancer reseach[1].
Product Specifications
UNSPSC
12352005
Target
Akt; Apoptosis; Epigenetic Reader Domain; FOXO; PI3K; PTEN; ROCK
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
N#CC1=CC=C(C=C1C(F)(F)F)NC(NC2=CC=C3C=NC=CC3=C2)=S
Molecular Formula
C18H11F3N4S
Molecular Weight
372.37
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Akt; FOXO1; PI3K; ROCK2
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
PCOLCE (Procollagen C-endopeptidase Enhancer, Procollagen C-endopeptidase Enhancer 1, PCPE, PCPE1, PCPE-1) (FITC)
PCOLCE (Procollagen C-endopeptidase Enhancer, Procollagen C-endopeptidase Enhancer 1, PCPE, PCPE1, PCPE-1) (FITC)